Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450(CYP17) and steroid 5?-reductase type II(SRD5A2) genes on prostate-cancer risk among the Japanese population
- 1 June 2001
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 92 (5) , 683-686
- https://doi.org/10.1002/1097-0215(20010601)92:5<683::aid-ijc1255>3.0.co;2-4
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- A polymorphism in theCYP17 gene is associated with prostate cancer riskInternational Journal of Cancer, 2000
- Prostate cancer associated with CYP17 genotypePharmacogenetics, 1999
- Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2)Carcinogenesis: Integrative Cancer Research, 1999
- Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USAThe Lancet, 1999
- Prospective Study of Sex Hormone Levels and Risk of Prostate CancerJNCI Journal of the National Cancer Institute, 1996
- Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17Human Molecular Genetics, 1994
- 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black malesThe Lancet, 1992
- Genes Involved in Androgen Biosynthesis and the Male PhenotypeHormone Research, 1992
- Possible Underestimation of the Incidence Rate of Prostate Cancer in JapanJapanese Journal of Cancer Research, 1991